BR112012017348A2 - "análogo de peptídeo de oxintomodulina" - Google Patents

"análogo de peptídeo de oxintomodulina"

Info

Publication number
BR112012017348A2
BR112012017348A2 BR112012017348A BR112012017348A BR112012017348A2 BR 112012017348 A2 BR112012017348 A2 BR 112012017348A2 BR 112012017348 A BR112012017348 A BR 112012017348A BR 112012017348 A BR112012017348 A BR 112012017348A BR 112012017348 A2 BR112012017348 A2 BR 112012017348A2
Authority
BR
Brazil
Prior art keywords
peptide analog
oxintomodulin
oxintomodulin peptide
analog
oxytomodulin
Prior art date
Application number
BR112012017348A
Other languages
English (en)
Other versions
BR112012017348B1 (pt
Inventor
Alsina-Fernandez Jorge
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43587001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012017348(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112012017348A2 publication Critical patent/BR112012017348A2/pt
Publication of BR112012017348B1 publication Critical patent/BR112012017348B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

patente de invenção: "análogo de peptídeo de oxintomodulina". a presente invenção refere-se a um análogo de peptídeo de oxintomodulina últil no tratamento de diabetes e/ou obsidade.
BR112012017348A 2009-12-22 2010-12-15 análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica BR112012017348B1 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28888809P 2009-12-22 2009-12-22
US35257610P 2010-06-08 2010-06-08
PCT/US2010/060390 WO2011087672A1 (en) 2009-12-22 2010-12-15 Oxyntomodulin peptide analogue
US12/968,382 US8367607B2 (en) 2009-12-22 2010-12-15 Oxyntomodulin peptide analogue

Publications (2)

Publication Number Publication Date
BR112012017348A2 true BR112012017348A2 (pt) 2017-01-10
BR112012017348B1 BR112012017348B1 (pt) 2019-11-05

Family

ID=43587001

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012017348A BR112012017348B1 (pt) 2009-12-22 2010-12-15 análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica

Country Status (34)

Country Link
US (1) US8367607B2 (pt)
EP (1) EP2515928B1 (pt)
JP (1) JP5717759B2 (pt)
KR (1) KR101399671B1 (pt)
CN (1) CN102740873B (pt)
AR (1) AR079345A1 (pt)
AU (1) AU2010341651B2 (pt)
BR (1) BR112012017348B1 (pt)
CA (1) CA2784671C (pt)
CL (1) CL2012001686A1 (pt)
CO (1) CO6551738A2 (pt)
CR (1) CR20120338A (pt)
DK (1) DK2515928T3 (pt)
DO (1) DOP2012000176A (pt)
EA (1) EA022820B1 (pt)
ES (1) ES2486675T3 (pt)
HK (1) HK1170941A1 (pt)
HN (1) HN2012001321A (pt)
HR (1) HRP20140616T1 (pt)
IL (1) IL220161B (pt)
JO (1) JO2976B1 (pt)
MA (1) MA33825B1 (pt)
MX (1) MX2012007438A (pt)
MY (1) MY160773A (pt)
NZ (1) NZ600731A (pt)
PE (1) PE20121393A1 (pt)
PL (1) PL2515928T3 (pt)
PT (1) PT2515928E (pt)
RS (1) RS53505B1 (pt)
SG (1) SG181430A1 (pt)
SI (1) SI2515928T1 (pt)
TN (1) TN2012000302A1 (pt)
TW (1) TWI423812B (pt)
WO (1) WO2011087672A1 (pt)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
ES2507098T3 (es) 2005-11-07 2014-10-14 Indiana University Research And Technology Corporation Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
KR101200728B1 (ko) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 삼투성 전달 시스템 및 피스톤 조립체
KR20150116465A (ko) 2007-02-15 2015-10-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
MX2010004297A (es) 2007-10-30 2010-05-03 Univ Indiana Res & Tech Corp Antagonistas de glucagon.
MX2010004298A (es) 2007-10-30 2010-05-03 Univ Indiana Res & Tech Corp Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
EP2300035B1 (en) 2008-06-17 2015-08-12 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
PE20120332A1 (es) 2008-12-19 2012-04-14 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida
EP2443146B1 (en) 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
MX352878B (es) 2009-09-28 2017-12-13 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
US8551946B2 (en) 2010-01-27 2013-10-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
KR20130111923A (ko) 2010-05-13 2013-10-11 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
BR112012028704A2 (pt) 2010-05-13 2019-09-24 Univ Indiana Res & Tech Corp composto de glugagon da superfamília de peptídeos exibindo atividade do receptor com hormônio nuclear, pró fármaco, dímero ou multímero, composição farmacêutica que o compreendem e método de administração do mesmo.
CN103458920B (zh) 2010-12-22 2016-07-06 印第安那大学科技研究公司 表现出gip受体活性的胰高血糖素类似物
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
AU2012267398B2 (en) 2011-06-10 2016-10-13 Hanmi Science Co., Ltd. Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
RU2733544C2 (ru) 2011-06-17 2020-10-05 Ханми Сайенс Ко., Лтд. Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение
CA2839686C (en) 2011-06-22 2019-12-24 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
KR20140043793A (ko) 2011-06-22 2014-04-10 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/glp-1 수용체 공동-작용물질
BR112014007124A2 (pt) 2011-11-17 2017-06-13 Univ Indiana Res & Tech Corp superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
PE20142405A1 (es) 2012-04-19 2015-01-25 Opko Biolog Ltd Variantes de oxintomodulina de accion prolongada y metodos de produccion de las mismas
IN2015DN00003A (pt) 2012-06-04 2015-05-22 Opko Biolog Ltd
JP6311708B2 (ja) 2012-06-21 2018-04-18 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Ｇｉｐ受容体活性を示すグルカゴンアナローグ
KR101968344B1 (ko) * 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EA039082B1 (ru) 2012-11-06 2021-12-01 Ханми Фарм. Ко., Лтд. Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина
KR101993393B1 (ko) * 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
ES2882890T3 (es) 2012-11-20 2021-12-03 Opko Biologics Ltd Método para aumentar el volumen hidrodinámico de polipéptidos mediante la unión a péptidos carboxi terminales de la gonadotrofina
EP2934569A1 (en) 2012-12-21 2015-10-28 Sanofi Exendin-4 derivatives
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
EP4278996A3 (en) 2015-06-03 2024-01-24 i2o Therapeutics, Inc. Implant placement systems
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016203482A2 (en) 2015-06-19 2016-12-22 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
AR104932A1 (es) 2015-06-22 2017-08-23 Lilly Co Eli Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US20190160152A1 (en) 2016-06-09 2019-05-30 Opko Biologics Ltd. Long-acting oxyntomodulin formulation and methods of producing and administering same
BR112019000610A2 (pt) 2016-07-11 2019-07-02 Opko Biologics Ltd fator vii de coagulação de longa ação e métodos de produção do mesmo
TW201832783A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
CN108299553B (zh) * 2017-01-13 2021-07-16 博瑞生物医药（苏州）股份有限公司 胃泌酸调节素修饰物
CN112912095A (zh) 2018-07-19 2021-06-04 D&D制药技术股份有限公司 包括多肽的药物组合物
KR101990075B1 (ko) * 2018-07-19 2019-06-18 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비만 예방 또는 치료용 약학 조성물
KR20200135618A (ko) * 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
US20200262887A1 (en) 2018-11-30 2020-08-20 Opko Ireland Global Holdings, Ltd. Oxyntomodulin peptide analog formulations

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5445090A (en) 1991-07-25 1995-08-29 Mim Industries, Inc. Interchangeable clamp for use in a sewing machine
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
CA2204645A1 (en) * 1994-11-07 1996-05-17 Keiichi Yano Novel oxyntomodulin
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
DK1411075T3 (da) 1998-03-12 2008-10-27 Nektar Therapeutics Al Corp Fremgangsmåde til fremstilling af polymerkonjugater
MXPA02006216A (es) 1999-12-22 2004-02-26 Nektar Therapeutics Al Corp Derivados estericamente impedidos de polimeros solubles en agua.
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
UA92451C2 (en) 2003-03-19 2010-11-10 Эли Лилли Энд Компани Polyethelene glycol link glp-1 compounds
PT1881850E (pt) 2005-05-13 2010-11-26 Lilly Co Eli Compostos peguilados de glp-1
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
EP2351776A1 (en) 2005-06-13 2011-08-03 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
ES2507098T3 (es) 2005-11-07 2014-10-14 Indiana University Research And Technology Corporation Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
CA2638800A1 (en) * 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
KR20150116465A (ko) 2007-02-15 2015-10-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
JP5385266B2 (ja) 2007-06-15 2014-01-08 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
WO2009030771A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
AR079344A1 (es) * 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad

Also Published As

Publication number Publication date
DOP2012000176A (es) 2012-08-31
CR20120338A (es) 2012-07-23
TWI423812B (zh) 2014-01-21
JP5717759B2 (ja) 2015-05-13
US8367607B2 (en) 2013-02-05
WO2011087672A1 (en) 2011-07-21
PE20121393A1 (es) 2012-10-26
US20110152182A1 (en) 2011-06-23
AU2010341651B2 (en) 2014-01-16
DK2515928T3 (da) 2014-08-25
HRP20140616T1 (hr) 2014-08-15
SI2515928T1 (sl) 2014-08-29
TN2012000302A1 (en) 2013-12-12
PT2515928E (pt) 2014-09-03
ES2486675T3 (es) 2014-08-19
CA2784671A1 (en) 2011-07-21
KR20120096022A (ko) 2012-08-29
SG181430A1 (en) 2012-07-30
KR101399671B1 (ko) 2014-05-27
EP2515928A1 (en) 2012-10-31
JO2976B1 (en) 2016-03-15
IL220161B (en) 2018-12-31
RS53505B1 (en) 2015-02-27
TW201143793A (en) 2011-12-16
HK1170941A1 (en) 2013-03-15
BR112012017348B1 (pt) 2019-11-05
CN102740873A (zh) 2012-10-17
AU2010341651A1 (en) 2012-06-07
CN102740873B (zh) 2014-11-05
JP2013515057A (ja) 2013-05-02
IL220161A0 (en) 2012-07-31
AR079345A1 (es) 2012-01-18
HN2012001321A (es) 2015-08-31
PL2515928T3 (pl) 2014-11-28
MA33825B1 (fr) 2012-12-03
CA2784671C (en) 2015-06-16
MX2012007438A (es) 2012-07-17
MY160773A (en) 2017-03-15
EP2515928B1 (en) 2014-06-18
CO6551738A2 (es) 2012-10-31
EA022820B1 (ru) 2016-03-31
CL2012001686A1 (es) 2012-11-23
NZ600731A (en) 2014-06-27
EA201290549A1 (ru) 2013-01-30

Similar Documents

Publication Publication Date Title
BR112012017348A2 (pt) "análogo de peptídeo de oxintomodulina"
BR112012017054A2 (pt) "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica"
IL210364A (en) Beta-amyloid peptide cyclic peptide analogue and its use in the treatment and diagnosis of neurodegenerative diseases or conditions
IL179828A0 (en) Therapeutic agents for the treatment of hmgb1-related pathologies
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
MY158325A (en) Multitype peptide compositions and methods for treatment or prevention of human papillpmavirus infection
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
MX2012007416A (es) Composiciones y metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis.
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
WO2010135521A3 (en) Compositions and methods for the therapy and diagnosis of influenza
NO20090958L (no) Behandling av revmatismesykdom med langsom frigivelse av glukokortikoid
IN2012DN03096A (pt)
BR112012033045A2 (pt) tratamento de complicações vasculares do diabetes.
WO2010052243A3 (en) Neurotensin-derived branched peptides and uses thereof
ATE475670T1 (de) Konsensus-peptid
ECSP12011991A (es) Análogo peptídico de oxintomodulina
UA106465C2 (en) Oxyntomodulin peptide analogue
SG138488A1 (en) Novel polypeptides for anti-viral treatment
EA200900603A1 (ru) Применение тимозин альфа-1 для получения лекарственного средства для профилактики и лечения аллергических реакций
HK1153143A1 (en) Pharmaceutical composition for the treatment of type 2 diabetes in mammals including human beings
IT1397219B1 (it) Composizione farmaceutica o dietetica per il trattamento dell'atopia
MX2009002717A (es) Composiciones y metodos para tratamiento del sindrome de fatiga cronica y enfermedades neurodegenerativas.
CY1115268T1 (el) Αναλογο πεπτιδιο οξυντομοντουλινης
UY32428A (es) Derivados de n-[(2-aza-biciclo[2.1.1]hex-1-il)-aril-metil]-benzamida, su preparacion y su aplicacion en terapeutica
FR2949064B1 (fr) Nouvelles compositions destinees a la prevention et/ou au traitement du diabete

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/12/2010, OBSERVADAS AS CONDICOES LEGAIS.